Sanofi

Despite widespread media coverage of medical innovation, public trust in clinical research remains unchanged. The clinical research enterprise has failed to leverage popular culture and mass media effectively for education, contributing to enrollment challenges and low trust. Edutainment, combining education with entertainment, is proposed as a solution to improve clinical research literacy and trust.

Eli Lilly's experimental breast cancer drug, imlunestrant, met its main goal in a Phase 3 study, showing improved progression-free survival in HER2-negative, ER-positive patients. Combined with Verezenio, it offered longer survival and progression-free benefits. Imlunestrant, a next-gen SERD, aims to overcome resistance, particularly from ESR1 mutations. The trial enrolled 874 patients, with imlunestrant plus Verezenio reducing progression or death risk by 43% compared to imlunestrant alone. Side effects were higher with the combination treatment.

Sanofi's two non-mRNA combination vaccine candidates for flu and COVID-19 in individuals 50+ received FDA Fast Track designation. The candidates combine existing vaccines with proven efficacy and favorable tolerability, aiming for simpler scheduling and fewer injections. Studies show potential for increased vaccine uptake and reduced healthcare burden.

At ASH 2024, physicians discussed advancements in hemophilia care, including Roche's Hemlibra and curative AAV gene therapies like CSL Behring's Hemgenix, Biomarin's Roctavian, and Pfizer's Beqvez and Hympavzi. Despite progress, unmet needs remain, with concerns over long-term risks of gene therapies and limited access. Pfizer presented Phase III AFFINE trial data for giroctocogene fitelparvovec, showing comparable efficacy to Roctavian with better safety. Sanofi's fitusiran, a siRNA, demonstrated efficacy similar to clotting factor replacement therapy. Staidson's bemiltenase alfa, a fusion protein, showed favorable bleed clearance rates. Challenges persist, but advancements in curative, prophylaxis, and on-demand treatments offer more options for patients.

The FDA granted Fast Track designation to two Sanofi combination vaccine candidates for flu and COVID-19 prevention in individuals aged 50 and older. The candidates combine existing vaccines with proven efficacy and tolerability. Sanofi aims to develop a combined vaccine offering simpler scheduling and high efficacy, safety, and tolerability.

Sanofi's two combination vaccine candidates, NCT06695117 and NCT06695130, received Fast Track designation from the FDA for preventing influenza and COVID-19 in people aged 50+. These candidates combine Sanofi's Fluzone High-Dose or Flublok with Novavax's NVXC19 vaccine. Sanofi and Novavax have a deal for co-marketing NVXC19 from 2025, with Sanofi having sole rights to develop and market the combination with its influenza vaccines. Novavax's NVXC19 shows better tolerability and high efficacy. Sanofi's Vaccines unit has strong sales growth, expecting over €10 billion in annual net sales by 2030.

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.

Sanofi's two non-mRNA combination vaccine candidates for flu and COVID-19 received Fast Track designation in the US. The candidates combine licensed vaccines Fluzone High-Dose/Flublok with Novavax COVID-19 vaccine. Phase 1/2 studies are ongoing to assess safety and immune response. The vaccines aim for simpler scheduling and fewer injections while maintaining efficacy and tolerability.